These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12631591)

  • 1. MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma.
    Tatsumi T; Kierstead LS; Ranieri E; Gesualdo L; Schena FP; Finke JH; Bukowski RM; Brusic V; Sidney J; Sette A; Logan TF; Kasamon YL; Slingluff CL; Kirkwood JM; Storkus WJ
    Clin Cancer Res; 2003 Mar; 9(3):947-54. PubMed ID: 12631591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.
    Tatsumi T; Kierstead LS; Ranieri E; Gesualdo L; Schena FP; Finke JH; Bukowski RM; Mueller-Berghaus J; Kirkwood JM; Kwok WW; Storkus WJ
    J Exp Med; 2002 Sep; 196(5):619-28. PubMed ID: 12208877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells.
    Kierstead LS; Ranieri E; Olson W; Brusic V; Sidney J; Sette A; Kasamon YL; Slingluff CL; Kirkwood JM; Storkus WJ
    Br J Cancer; 2001 Nov; 85(11):1738-45. PubMed ID: 11742496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6.
    Vujanovic L; Mandic M; Olson WC; Kirkwood JM; Storkus WJ
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6796-806. PubMed ID: 18006782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein.
    Parkhurst MR; Riley JP; Robbins PF; Rosenberg SA
    J Immunother; 2004; 27(2):79-91. PubMed ID: 14770079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11.
    Manici S; Sturniolo T; Imro MA; Hammer J; Sinigaglia F; Noppen C; Spagnoli G; Mazzi B; Bellone M; Dellabona P; Protti MP
    J Exp Med; 1999 Mar; 189(5):871-6. PubMed ID: 10049951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes.
    Warrino DE; Olson WC; Knapp WT; Scarrow MI; D'Ambrosio-Brennan LJ; Guido RS; Edwards RP; Kast WM; Storkus WJ
    Clin Cancer Res; 2004 May; 10(10):3301-8. PubMed ID: 15161683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma.
    Tatsumi T; Herrem CJ; Olson WC; Finke JH; Bukowski RM; Kinch MS; Ranieri E; Storkus WJ
    Cancer Res; 2003 Aug; 63(15):4481-9. PubMed ID: 12907621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
    Mandic M; Castelli F; Janjic B; Almunia C; Andrade P; Gillet D; Brusic V; Kirkwood JM; Maillere B; Zarour HM
    J Immunol; 2005 Feb; 174(3):1751-9. PubMed ID: 15661941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes.
    Chaux P; Vantomme V; Stroobant V; Thielemans K; Corthals J; Luiten R; Eggermont AM; Boon T; van der Bruggen P
    J Exp Med; 1999 Mar; 189(5):767-78. PubMed ID: 10049940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries.
    Osen W; Soltek S; Song M; Leuchs B; Steitz J; Tüting T; Eichmüller SB; Nguyen XD; Schadendorf D; Paschen A
    PLoS One; 2010 Nov; 5(11):e14137. PubMed ID: 21152437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
    Zarour HM; Storkus WJ; Brusic V; Williams E; Kirkwood JM
    Cancer Res; 2000 Sep; 60(17):4946-52. PubMed ID: 10987311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3.
    Consogno G; Manici S; Facchinetti V; Bachi A; Hammer J; Conti-Fine BM; Rugarli C; Traversari C; Protti MP
    Blood; 2003 Feb; 101(3):1038-44. PubMed ID: 12393675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.
    Zarour HM; Kirkwood JM; Kierstead LS; Herr W; Brusic V; Slingluff CL; Sidney J; Sette A; Storkus WJ
    Proc Natl Acad Sci U S A; 2000 Jan; 97(1):400-5. PubMed ID: 10618430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules.
    Zeng G; Touloukian CE; Wang X; Restifo NP; Rosenberg SA; Wang RF
    J Immunol; 2000 Jul; 165(2):1153-9. PubMed ID: 10878395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.
    Jäger E; Jäger D; Karbach J; Chen YT; Ritter G; Nagata Y; Gnjatic S; Stockert E; Arand M; Old LJ; Knuth A
    J Exp Med; 2000 Feb; 191(4):625-30. PubMed ID: 10684854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein.
    Zhang Y; Sun Z; Nicolay H; Meyer RG; Renkvist N; Stroobant V; Corthals J; Carrasco J; Eggermont AM; Marchand M; Thielemans K; Wölfel T; Boon T; van der Bruggen P
    J Immunol; 2005 Feb; 174(4):2404-11. PubMed ID: 15699177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
    Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
    Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
    Schultz ES; Schuler-Thurner B; Stroobant V; Jenne L; Berger TG; Thielemanns K; van der Bruggen P; Schuler G
    J Immunol; 2004 Jan; 172(2):1304-10. PubMed ID: 14707109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro.
    Vujanovic L; Ranieri E; Gambotto A; Olson WC; Kirkwood JM; Storkus WJ
    Cancer Gene Ther; 2006 Aug; 13(8):798-805. PubMed ID: 16645618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.